KLF5 (Krüppel-like factor 5) is a transcription factor belonging to the Krüppel-like family, characterized by its zinc finger DNA-binding domain. It plays dual roles in cellular processes, regulating genes involved in proliferation, differentiation, apoptosis, and tissue homeostasis. KLF5 is highly expressed in epithelial tissues and is implicated in cancer (e.g., promoting tumor growth in breast, colorectal, and prostate cancers), cardiovascular diseases (e.g., vascular remodeling), and stem cell biology. Its activity is modulated by post-translational modifications and interactions with signaling pathways like Wnt/β-catenin and TGF-β.
KLF5 antibodies are essential tools for detecting and quantifying KLF5 protein levels in research. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP). These antibodies aid in studying KLF5’s expression patterns, subcellular localization, and regulatory mechanisms across disease models. Commercial KLF5 antibodies vary in specificity (e.g., targeting different epitopes or modified forms) and host sources (e.g., rabbit, mouse). Validation using knockout controls or siRNA-mediated knockdown is critical to confirm antibody reliability. Applications span cancer biomarker studies, drug discovery (e.g., targeting KLF5-associated pathways), and regenerative medicine, underscoring their importance in understanding KLF5’s context-dependent roles in health and disease.